RarePlex PD-L1 CTC Panel Kit

RareCyte’s programmed death ligand 1 (PD-L1) circulating tumor cell assay provides highly accurate, repeatable, and precise results for circulating tumor cell count and PD-L1 biomarker expression, and is suitable for use in large, multi-center clinical trials. The assay includes processing blood to slides with the AccuCyte^® Sample Preparation System followed by staining with the RarePlex 0912-VB PD-L1 CTC Panel Kit and imaging on a CyteFinder^® Instrument. Machine learning enabled analysis and scoring maximizes reviewer concordance.

This PD-L1 assay is deployed on RareCyte’s circulating tumor cell analysis platform with:

• Simple processing of blood to slides for sample banking
• Convenient pause points in workflow enable sample control and transport
• Flexibility in sample handling – processing and analysis may be performed at the same site or at a separate clinical research laboratory when desired
• Extensive validation and highly automated process yield accurate and highly reproducible results
• Worldwide network of contract research organizations (CROs) to support global clinical trials

SW900 (PD-L1 high), H1650 (PD-L1 low), and HAP-1 (PD-L1 negative) cell lines are shown. The top row represents a merge image where Nuclei = blue, CD45 = green, and CK/EpCAM = magenta. The PD-L1 localization in the bottom row matches expected expression levels. Speckled PD-L1 signal surrounding the mCTCs and WBCs is consistent with staining of background platelets, which are known to express PD-L1 protein (Rolfes V, et al. Oncotarget 9(44):27460).
Scale bar represents 10μm.